# Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/attention-deficit-hyperactivity-disorder-developing-stimulant-drugs-for-treatment-guidance-for-industry/0fcd99c6-644f-41df-81ff-6f0bd09628b2

> FDA guidance document: Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry. Issue date: May 06, 2019. Get complete insights and analysis.

---

## Details

- Title: Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-05-06
- Comment Close Date: 2019-07-03
- Last Changed: 2024-04-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-0849">FDA-2019-D-0849</a>

## Related Documents

- [Stimulant Use Disorders: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/stimulant-use-disorders-developing-drugs-for-treatment/396da81b-e089-444c-9781-b40a43a1cff2)
- [Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/nonalcoholic-steatohepatitis-with-compensated-cirrhosis-developing-drugs-for-treatment-guidance-for-industry/71c114f5-4930-4cda-87ef-12936678931f)
- [Major Depressive Disorder:  Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/major-depressive-disorder-developing-drugs-for-treatment/8f70f512-6f81-4d11-86f6-e2abe0d6dcc0)